MBX Biosciences, Inc. Share Price
MBXMBX Biosciences, Inc. Stock Performance
Open $62.73 | Prev. Close $62.88 | Circuit Range N/A |
Day Range $59.80 - $62.95 | Year Range $9.64 - $66.34 | Volume 42,640 |
Average Traded $60.54 |
MBX Biosciences, Inc. Share Price Chart
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX Biosciences, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
20-Jul-26 | $62.73 | $60.13 | +0.00% |
20-Jul-26 | $62.73 | $60.13 | -4.37% |
17-Jul-26 | $56.67 | $62.88 | +7.75% |
16-Jul-26 | $59.05 | $58.36 | -3.79% |
15-Jul-26 | $55.45 | $60.66 | +7.17% |
14-Jul-26 | $56.00 | $56.60 | -5.68% |
13-Jul-26 | $59.50 | $60.01 | -1.62% |